Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Akero Therapeutics (Nasdaq: AKRO), a clinical-stage company focused on developing treatments for serious metabolic diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a presentation on Tuesday, January 14, 2025, at 11:15 a.m. Pacific Time.
Interested parties can access a live webcast of the presentation through the investor relations section of Akero's website at www.akerotx.com. An archived version of the presentation will also be made available on the company's website following the live broadcast.
Akero Therapeutics (Nasdaq: AKRO), una società in fase clinica focalizzata sullo sviluppo di trattamenti per gravi malattie metaboliche, ha annunciato la sua partecipazione al 43° Conferenza Annuale J.P. Morgan Healthcare. La direzione dell'azienda terrà una presentazione martedì 14 gennaio 2025, alle 11:15 ora del Pacifico.
Le parti interessate possono accedere a una webcasting dal vivo della presentazione attraverso la sezione relazioni con gli investitori del sito web di Akero all'indirizzo www.akerotx.com. Una versione registrata della presentazione sarà inoltre disponibile sul sito dell'azienda dopo la trasmissione dal vivo.
Akero Therapeutics (Nasdaq: AKRO), una empresa en etapa clínica centrada en el desarrollo de tratamientos para enfermedades metabólicas graves, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan. La dirección de la empresa realizará una presentación el martes 14 de enero de 2025, a las 11:15 a.m. hora del Pacífico.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de relaciones con inversionistas del sitio web de Akero en www.akerotx.com. También se pondrá a disposición una versión archivada de la presentación en el sitio web de la empresa tras la transmisión en vivo.
Akero Therapeutics (Nasdaq: AKRO)는 심각한 대사 질환에 대한 치료법 개발에 중점을 둔 임상 단계 회사로, 제43회 연례 J.P. Morgan 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 1월 14일 화요일 태평양 시간 기준 오전 11시 15분에 발표를 진행할 예정입니다.
관심 있는 당사자들은 Akero의 웹사이트 www.akerotx.com의 투자자 관계 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 실시간 방송 후에는 회사 웹사이트에서 발표의 아카이브 버전도 제공될 예정입니다.
Akero Therapeutics (Nasdaq: AKRO), une entreprise en phase clinique axée sur le développement de traitements pour des maladies métaboliques graves, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. La direction de l'entreprise fera une présentation le mardi 14 janvier 2025, à 11h15, heure du Pacifique.
Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section relations investisseurs du site web d'Akero à l'adresse www.akerotx.com. Une version archivée de la présentation sera également disponible sur le site de l'entreprise après la diffusion en direct.
Akero Therapeutics (Nasdaq: AKRO), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für schwerwiegende Stoffwechselerkrankungen konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Das Management des Unternehmens wird am Dienstag, dem 14. Januar 2025, um 11:15 Uhr pazifischer Zeit eine Präsentation halten.
Interessierte Parteien können über den Bereich Investor Relations auf der Website von Akero unter www.akerotx.com auf einen Live-Stream der Präsentation zugreifen. Eine aufgezeichnete Version der Präsentation wird ebenfalls nach der Live-Übertragung auf der Website des Unternehmens erhältlich sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. P.T.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero’s lead product candidate, EFX, is currently being evaluated in three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH (F2-F3) or compensated cirrhosis (F4) due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the completed HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the ongoing SYMMETRY study in patients with compensated cirrhosis (F4) due to MASH, in which more than 300 patients have been treated with EFX or placebo for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
Christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com
FAQ
When is Akero Therapeutics (AKRO) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch Akero Therapeutics' J.P. Morgan Healthcare Conference presentation?
What is the focus of Akero Therapeutics' (AKRO) drug development program?
Which annual J.P. Morgan Healthcare Conference is AKRO presenting at?
